secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2022-10-07T23:59:59+00:00
Accession:  0001104659-22-106936
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune secures $200M non-dilutive debt facility from Hercules Capital
------------------------------------------------------------------------

- $200M term loan; $30M funded at closing, $30M available by Sep 30, 2023.
- Up to $115M available upon clinical/regulatory/commercial milestones; $25M subject to Hercules consent.
- Interest: floating cash rate (greater of 7.25% or Prime+1.75% capped at 7.25%) plus 1.50% PIK.
- At least 48 months interest-only, extendable to 60 months on milestone achievement; matures Oct 2027.
- Proceeds extend cash runway into 2025 ahead of CERPASS/IGNYTE trial catalysts and commercial prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/0001104659-22-106936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/tm2227789d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-106936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer